ClOpidogrel - bienvenue sur le site de l'amiform

ClOpidogrel - bienvenue sur le site de l'amiform ClOpidogrel - bienvenue sur le site de l'amiform

08.01.2015 Views

Le traitement pour améliorer le pronostic: les IEC Event rate (%) Favors ACE inhibitor Favors Placebo Composite outcome CV mortality Myocardial infarction Stroke Cardiac arrest IEC Placebo 14.0 17.8 8.0 9.9 6.1 8.1 3.5 4.1 9.9 12.3 4.8 6.2 3.4 4.9 1.6 1.7 0.8 1.3 0.1 0.2 HOPE (ramipril 10 mg) EUROPA (perindopril 8 mg) 0.5 1.0 1.5 Hazard ratio HOPE Study Investigators. N Engl J Med. 2000;342:145-53. EUROPA Investigators. Lancet. 2003;362:782-8.

Le traitement pour améliorer le pronostic: les IEC les études % Patients % Patients 20 15 10 5 0 30 25 20 15 10 5 0 0 1 HOPE 22% Risk reduction RR 0.78 (0.70–0.86) P = 0.001 PEACE Placebo 2 3 4 Time (years) 4% Risk reduction HR 0.96 (0.88–1.06) P = 0.43 Placebo 1 2 3 4 5 Time (years) Ramipril 10 mg Trandolapril 4 mg 6 Critère composite constitué de la mortalité cardiovasculaire, des IDM non fatals et des revascularisations coronaires 50 40 30 20 10 0 14 12 10 8 6 4 2 0 0 0 EUROPA 20% Risk reduction RR 0.80 (0.71–0.91) P = 0.0003 1 2 3 4 Time (years) 4% Risk increase RR 1.04 (0.89–1.22) P = 0.6 1 QUIET Placebo Perindopril 8 mg 5 Quinapril 20 mg Placebo 2 3 Time (years)

Le traitement pour améliorer <strong>le</strong> pronostic:<br />

<strong>le</strong>s IEC <strong>le</strong>s étu<strong>de</strong>s<br />

%<br />

Patients<br />

%<br />

Patients<br />

20<br />

15<br />

10<br />

5<br />

0<br />

30<br />

25<br />

20<br />

15<br />

10<br />

5<br />

0<br />

0<br />

1<br />

HOPE<br />

22% Risk reduction<br />

RR 0.78 (0.70–0.86)<br />

P = 0.001<br />

PEACE<br />

Placebo<br />

2 3 4<br />

Time (years)<br />

4% Risk reduction<br />

HR 0.96 (0.88–1.06)<br />

P = 0.43<br />

Placebo<br />

1 2 3 4 5<br />

Time (years)<br />

Ramipril<br />

10 mg<br />

Trandolapril<br />

4 mg<br />

6<br />

Critère compo<strong>site</strong> constitué <strong>de</strong> la mortalité cardiovasculaire,<br />

<strong>de</strong>s IDM non fatals et <strong>de</strong>s revascularisations coronaires<br />

50<br />

40<br />

30<br />

20<br />

10<br />

0<br />

14<br />

12<br />

10<br />

8<br />

6<br />

4<br />

2<br />

0<br />

0<br />

0<br />

EUROPA<br />

20% Risk reduction<br />

RR 0.80 (0.71–0.91)<br />

P = 0.0003<br />

1 2 3 4<br />

Time (years)<br />

4% Risk increase<br />

RR 1.04 (0.89–1.22)<br />

P = 0.6<br />

1<br />

QUIET<br />

Placebo<br />

Perindopril<br />

8 mg<br />

5<br />

Quinapril<br />

20 mg<br />

Placebo<br />

2 3<br />

Time (years)

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!